mazdutide vs survodutide

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Obesity

Shared mechanism: GLP-1/glucagon receptor (dual) · full Obesity pipeline

mazdutide

Marketed by Innovent Biologics under a licence from Eli Lilly

Phase 3 in Obesitypeptide
Reliable signal

NCT05607680 · Phase 3 · completed

GLORY-1 was a randomized, double-blind, placebo-controlled Phase 3 trial in China. It assigned 610 adults with obesity or overweight to mazdutide 4 mg, mazdutide 6 mg or placebo once weekly. The two primary endpoints at week 32 were the percent change in body weight and the proportion of participants who lost at least 5% of their body weight. Both doses were significantly better than placebo on both endpoints (P<0.001 for all comparisons), so the trial met its primary endpoints. The figures come from the peer-reviewed paper in the New England Journal of Medicine.

Next expected readout: December 2026 · NCT06884293 (registry estimate)

Reported efficacy

Co-primary: percent change in body weight from baseline to week 32, and proportion of participants with at least 5% body-weight reduction at week 32: Co-primary 1, percent change in body weight from baseline to week 32 (treatment-policy estimand): mazdutide 4 mg -10.09% (95% CI -11.15 to -9.04), 6 mg -12.55% (95% CI -13.64 to -11.45) vs placebo +0.45% (95% CI -0.61 to 1.52); P<0.001 for both doses vs placebo, met. Co-primary 2, weight reduction of at least 5% at week 32: 73.9% (4 mg) and 82.0% (6 mg) vs 10.5% (placebo); P<0.001 for both doses vs placebo, met. (met)

Result source: NCT05607680

survodutide

Developed by Boehringer Ingelheim under a licence from Zealand Pharma

Phase 3 in Obesitypeptide
Partial signal

NCT06077864 · Phase 3 · completed

The study randomly assigns 5,531 participants to two survodutide doses or placebo and uses quadruple blinding. Its primary endpoint is a hard clinical composite of cardiovascular death, nonfatal stroke, nonfatal heart attack, coronary revascularization, or heart-failure events, but the non-inferiority result is not yet available.

Next expected readout: December 2026 · NCT07768813 (registry estimate)

Reported efficacy

Percentage change in body weight from baseline to Week 76 (Baseline and at Week 76); Achievement of body weight reduction ≥5% (yes/no) from baseline to Week 76 (Baseline and at Week 76): Percentage change in body weight from baseline to Week 76 (SYNCHRONIZE-1, primary analysis, treatment-regimen estimand): -13.0% survodutide 6.0 mg and -12.2% 3.6 mg vs -5.4% placebo; body weight reduction of at least 5%: 71.9% and 72.6% vs 46.3% (P<0.001 for all comparisons with placebo). (met)

Result source: NCT06066515

Results for Obesity

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointmazdutidesurvodutide
Body weight, % change-7.3% vs -0.8%−6.5 vs placebo3/6 mg · wk 32 · n 32NCT06124807
7 other results
  • -18.1% vs -0.8% 16 mg · wk 32 · n 51 · Phase 2 · primary NCT06124807
  • -15.6% vs -0.8% 10 mg · wk 32 · n 48 · Phase 2 · primary NCT06124807
  • -10.5% vs -0.0% 3/6 mg · wk 48 · n 32 · Phase 2 · secondary NCT06124807
  • -22.3% vs -0.0% 16 mg · wk 48 · n 51 · Phase 2 · secondary NCT06124807
  • -19.2% vs -0.0% 10 mg · wk 48 · n 48 · Phase 2 · secondary NCT06124807
  • -12.6% vs 0.5% mazdutide 6mg · wk 32 · Phase 3 · primary NCT05607680
  • -10.1% vs 0.5% mazdutide 4mg · wk 32 · Phase 3 · primary NCT05607680
-14.9% vs -2.8%−12.1 vs placebo4.8 mg · wk 46 · n 76NCT04667377
4 other results
  • -13.2% vs -2.8% 3.6 mg · wk 46 · n 76 · Phase 2 · primary NCT04667377
  • -12.5% vs -2.8% 2.4 mg · wk 46 · n 78 · Phase 2 · primary NCT04667377
  • -6.2% vs -2.8% 0.6 mg · wk 46 · n 76 · Phase 2 · primary NCT04667377
  • -16.6% vs -3.2% wk 76 · Phase 3 · primary NCT06066515
Weight loss of 5% or more74.8% vs 26.0%+48.8 vs placebo3/6 mg · wk 48 · n 32NCT06124807
5 other results
  • 67.6% vs 24.0% 3/6 mg · wk 32 · n 32 · Phase 2 · secondary NCT06124807
  • 91.9% vs 26.0% 16 mg · wk 48 · n 51 · Phase 2 · secondary NCT06124807
  • 92.2% vs 24.0% 16 mg · wk 32 · n 51 · Phase 2 · secondary NCT06124807
  • 95.9% vs 26.0% 10 mg · wk 48 · n 48 · Phase 2 · secondary NCT06124807
  • 96.1% vs 24.0% 10 mg · wk 32 · n 48 · Phase 2 · secondary NCT06124807
82.8% vs 25.9%+56.9 vs placebo4.8 mg · wk 46 · n 64NCT04667377
3 other results
  • 82% vs 25.9% 3.6 mg · wk 46 · n 61 · Phase 2 · secondary NCT04667377
  • 81% vs 25.9% 2.4 mg · wk 46 · n 58 · Phase 2 · secondary NCT04667377
  • 60.7% vs 25.9% 0.6 mg · wk 46 · n 56 · Phase 2 · secondary NCT04667377
Weight loss of 10% or more57.9% vs 13.8%+44.1 vs placebo3/6 mg · wk 48 · n 32NCT06124807
5 other results
  • 45.4% vs 8.7% 3/6 mg · wk 32 · n 32 · Phase 2 · secondary NCT06124807
  • 80.7% vs 13.8% 16 mg · wk 48 · n 51 · Phase 2 · secondary NCT06124807
  • 77.1% vs 8.7% 16 mg · wk 32 · n 51 · Phase 2 · secondary NCT06124807
  • 84.0% vs 13.8% 10 mg · wk 48 · n 48 · Phase 2 · secondary NCT06124807
  • 86.0% vs 8.7% 10 mg · wk 32 · n 48 · Phase 2 · secondary NCT06124807
68.8% vs 11.1%+57.7 vs placebo4.8 mg · wk 46 · n 64NCT04667377
3 other results
  • 65.6% vs 11.1% 3.6 mg · wk 46 · n 61 · Phase 2 · secondary NCT04667377
  • 65.5% vs 11.1% 2.4 mg · wk 46 · n 58 · Phase 2 · secondary NCT04667377
  • 33.9% vs 11.1% 0.6 mg · wk 46 · n 56 · Phase 2 · secondary NCT04667377
Waist circumference, change (cm)—Not posted · NCT05607680-16.0 vs -4.0−12 vs placebo4.8 mg · wk 46 · n 75NCT04667377
3 other results
  • -15.0 vs -4.0 3.6 mg · wk 46 · n 74 · Phase 2 · secondary NCT04667377
  • -15.0 vs -4.0 2.4 mg · wk 46 · n 71 · Phase 2 · secondary NCT04667377
  • -8.3 vs -4.0 0.6 mg · wk 46 · n 71 · Phase 2 · secondary NCT04667377

Body weight, % change

mazdutide
-7.3% vs -0.8%−6.5 vs placebo3/6 mg · wk 32 · n 32NCT06124807
7 other results
  • -18.1% vs -0.8% 16 mg · wk 32 · n 51 · Phase 2 · primary NCT06124807
  • -15.6% vs -0.8% 10 mg · wk 32 · n 48 · Phase 2 · primary NCT06124807
  • -10.5% vs -0.0% 3/6 mg · wk 48 · n 32 · Phase 2 · secondary NCT06124807
  • -22.3% vs -0.0% 16 mg · wk 48 · n 51 · Phase 2 · secondary NCT06124807
  • -19.2% vs -0.0% 10 mg · wk 48 · n 48 · Phase 2 · secondary NCT06124807
  • -12.6% vs 0.5% mazdutide 6mg · wk 32 · Phase 3 · primary NCT05607680
  • -10.1% vs 0.5% mazdutide 4mg · wk 32 · Phase 3 · primary NCT05607680
survodutide
-14.9% vs -2.8%−12.1 vs placebo4.8 mg · wk 46 · n 76NCT04667377
4 other results
  • -13.2% vs -2.8% 3.6 mg · wk 46 · n 76 · Phase 2 · primary NCT04667377
  • -12.5% vs -2.8% 2.4 mg · wk 46 · n 78 · Phase 2 · primary NCT04667377
  • -6.2% vs -2.8% 0.6 mg · wk 46 · n 76 · Phase 2 · primary NCT04667377
  • -16.6% vs -3.2% wk 76 · Phase 3 · primary NCT06066515

Weight loss of 5% or more

mazdutide
74.8% vs 26.0%+48.8 vs placebo3/6 mg · wk 48 · n 32NCT06124807
5 other results
  • 67.6% vs 24.0% 3/6 mg · wk 32 · n 32 · Phase 2 · secondary NCT06124807
  • 91.9% vs 26.0% 16 mg · wk 48 · n 51 · Phase 2 · secondary NCT06124807
  • 92.2% vs 24.0% 16 mg · wk 32 · n 51 · Phase 2 · secondary NCT06124807
  • 95.9% vs 26.0% 10 mg · wk 48 · n 48 · Phase 2 · secondary NCT06124807
  • 96.1% vs 24.0% 10 mg · wk 32 · n 48 · Phase 2 · secondary NCT06124807
survodutide
82.8% vs 25.9%+56.9 vs placebo4.8 mg · wk 46 · n 64NCT04667377
3 other results
  • 82% vs 25.9% 3.6 mg · wk 46 · n 61 · Phase 2 · secondary NCT04667377
  • 81% vs 25.9% 2.4 mg · wk 46 · n 58 · Phase 2 · secondary NCT04667377
  • 60.7% vs 25.9% 0.6 mg · wk 46 · n 56 · Phase 2 · secondary NCT04667377

Weight loss of 10% or more

mazdutide
57.9% vs 13.8%+44.1 vs placebo3/6 mg · wk 48 · n 32NCT06124807
5 other results
  • 45.4% vs 8.7% 3/6 mg · wk 32 · n 32 · Phase 2 · secondary NCT06124807
  • 80.7% vs 13.8% 16 mg · wk 48 · n 51 · Phase 2 · secondary NCT06124807
  • 77.1% vs 8.7% 16 mg · wk 32 · n 51 · Phase 2 · secondary NCT06124807
  • 84.0% vs 13.8% 10 mg · wk 48 · n 48 · Phase 2 · secondary NCT06124807
  • 86.0% vs 8.7% 10 mg · wk 32 · n 48 · Phase 2 · secondary NCT06124807
survodutide
68.8% vs 11.1%+57.7 vs placebo4.8 mg · wk 46 · n 64NCT04667377
3 other results
  • 65.6% vs 11.1% 3.6 mg · wk 46 · n 61 · Phase 2 · secondary NCT04667377
  • 65.5% vs 11.1% 2.4 mg · wk 46 · n 58 · Phase 2 · secondary NCT04667377
  • 33.9% vs 11.1% 0.6 mg · wk 46 · n 56 · Phase 2 · secondary NCT04667377

Waist circumference, change (cm)

mazdutide
—Not posted · NCT05607680
survodutide
-16.0 vs -4.0−12 vs placebo4.8 mg · wk 46 · n 75NCT04667377
3 other results
  • -15.0 vs -4.0 3.6 mg · wk 46 · n 74 · Phase 2 · secondary NCT04667377
  • -15.0 vs -4.0 2.4 mg · wk 46 · n 71 · Phase 2 · secondary NCT04667377
  • -8.3 vs -4.0 0.6 mg · wk 46 · n 71 · Phase 2 · secondary NCT04667377
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety

Coverage. mazdutide: 5 of 5 rows · survodutide: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricmazdutidesurvodutide
Rows use multiple source trials
Weight
absolute change · kg
-11.15 vs -0.15 placebo kg @ 48wk3/6 mga,b,c,d
NCT06124807 · Phase 2 · registry result, not featured evidence
show 2 more doses
-23.9 vs -0.15 placebo kg @ 48wk16 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
-19.7 vs -0.15 placebo kg @ 48wk10 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
-18.47 vs -2.68 placebo kg @ 46wk4.8 mga,b,c,d
NCT04667377 · Phase 2 · registry result, not featured evidence
show 3 more doses
-15.64 vs -2.68 placebo kg @ 46wk3.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
-14.75 vs -2.68 placebo kg @ 46wk2.4 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
-7.21 vs -2.68 placebo kg @ 46wk0.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
Dropout rate
12.5%3/6 mge
NCT06124807 · Phase 2 · registry result, not featured evidence
show 2 more results
33.3%16 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
22.9%10 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
—4.8 mge
NCT04667377 · Phase 2 · registry result, not featured evidence
show 7 more results
28.6%4.8 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
—3.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
23.4%3.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
—2.4 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
23.1%2.4 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
—0.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
29.5%0.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
0%3/6 mge
NCT06124807 · Phase 2 · registry result, not featured evidence
show 2 more results
9.8%16 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
4.2%10 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
—4.8 mge
NCT04667377 · Phase 2 · registry result, not featured evidence
show 7 more results
23.4%4.8 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
—3.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
18.2%3.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
—2.4 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
14.1%2.4 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
—0.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
16.7%0.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
Serious AEs
3.1%3/6 mge
NCT06124807 · Phase 2 · registry result, not featured evidence
show 2 more results
3.9%16 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
2.1%10 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
7.4%4.8 mge
NCT04667377 · Phase 2 · registry result, not featured evidence
show 7 more results
—4.8 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
5.6%3.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
—3.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
3.3%2.4 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
—2.4 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
2.2%0.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
—0.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
3/6 mge
nausea 43.8% (placebo 25.5%)
diarrhoea 28.1% (placebo 12.8%)
constipation 21.9% (placebo 10.6%)
NCT06124807 · Phase 2 · registry result, not featured evidence
show 2 more results
16 mg
nausea 66.7% (placebo 25.5%)
vomiting 47.1% (placebo 2.1%)
constipation 37.3% (placebo 10.6%)
NCT06124807 · Phase 2 · registry result, not featured evidence
10 mg
nausea 46.8% (placebo 25.5%)
constipation 29.8% (placebo 10.6%)
diarrhoea 25.5% (placebo 12.8%)
NCT06124807 · Phase 2 · registry result, not featured evidence
4.8 mge
nausea 59.3% (placebo 19.5%)
constipation 24.1% (placebo 5.2%)
vomiting 24.1% (placebo 5.2%)
NCT04667377 · Phase 2 · registry result, not featured evidence
show 3 more results
3.6 mg
nausea 63.4% (placebo 19.5%)
vomiting 39.4% (placebo 5.2%)
constipation 31% (placebo 5.2%)
NCT04667377 · Phase 2 · registry result, not featured evidence
2.4 mg
nausea 65.2% (placebo 19.5%)
vomiting 30.4% (placebo 5.2%)
diarrhoea 22.8% (placebo 10.4%)
NCT04667377 · Phase 2 · registry result, not featured evidence
0.6 mg
nausea 39.1% (placebo 19.5%)
diarrhoea 23.9% (placebo 10.4%)
covid-19 19.6% (placebo 22.1%)
NCT04667377 · Phase 2 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 46 weeks versus 48 weeks.
  5. ePopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

mazdutide

BMI -2.84 vs -0.32 placebo kg @ 32wk3/6 mg
absolute change · kg
NCT06124807 · Phase 2 · registry result, not featured evidence
show 5 more results
-4.07 vs -0.017 placebo kg @ 48wk3/6 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
-6.86 vs -0.32 placebo kg @ 32wk16 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
-8.53 vs -0.017 placebo kg @ 48wk16 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
-5.81 vs -0.32 placebo kg @ 32wk10 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
-7.15 vs -0.017 placebo kg @ 48wk10 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
Liver Fat -6.15% (n=22) vs -1.62% (n=36) placebo @ 32wk3/6 mg
absolute change · percentage points
NCT06124807 · Phase 2 · registry result, not featured evidence
show 11 more results
-7.81% (n=22) vs -1.35% (n=36) placebo @ 48wk3/6 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
-9.3% (n=11) vs -4.3% (n=19) placebo @ 32wk3/6 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
-12.4% (n=11) vs -4.6% (n=19) placebo @ 48wk3/6 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
-7.91% (n=31) vs -1.62% (n=36) placebo @ 32wk16 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
-7.74% (n=31) vs -1.35% (n=36) placebo @ 48wk16 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
-12.8% (n=18) vs -4.3% (n=19) placebo @ 32wk16 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
-12.6% (n=18) vs -4.6% (n=19) placebo @ 48wk16 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
-7.78% (n=33) vs -1.62% (n=36) placebo @ 32wk10 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
-8.07% (n=33) vs -1.35% (n=36) placebo @ 48wk10 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
-13.8% (n=19) vs -4.3% (n=19) placebo @ 32wk10 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
-13.9% (n=19) vs -4.6% (n=19) placebo @ 48wk10 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
Liver PDFF -53.5% (n=22) vs -14.1% (n=36) placebo @ 32wk3/6 mg
percent change · % of baseline
NCT06124807 · Phase 2 · registry result, not featured evidence
show 11 more results
-68% (n=22) vs -11.7% (n=36) placebo @ 48wk3/6 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
-53.4% (n=11) vs -24.7% (n=19) placebo @ 32wk3/6 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
-71.2% (n=11) vs -26.3% (n=19) placebo @ 48wk3/6 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
-68.8% (n=31) vs -14.1% (n=36) placebo @ 32wk16 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
-67.4% (n=31) vs -11.7% (n=36) placebo @ 48wk16 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
-73.6% (n=18) vs -24.7% (n=19) placebo @ 32wk16 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
-72.3% (n=18) vs -26.3% (n=19) placebo @ 48wk16 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
-67.7% (n=33) vs -14.1% (n=36) placebo @ 32wk10 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
-70.2% (n=33) vs -11.7% (n=36) placebo @ 48wk10 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
-79.5% (n=19) vs -24.7% (n=19) placebo @ 32wk10 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
-80.2% (n=19) vs -26.3% (n=19) placebo @ 48wk10 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
MRI-PDFF ≥30% 73.97% (n=22) vs 24.93% (n=36) placebo @ 32wk3/6 mg
responder rate · % of participants
NCT06124807 · Phase 2 · registry result, not featured evidence
show 11 more results
87.73% (n=22) vs 30.04% (n=36) placebo @ 48wk3/6 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
71.95% (n=11) vs 38.57% (n=19) placebo @ 32wk3/6 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
86.64% (n=11) vs 36.82% (n=19) placebo @ 48wk3/6 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
83.4% (n=31) vs 24.93% (n=36) placebo @ 32wk16 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
84.23% (n=31) vs 30.04% (n=36) placebo @ 48wk16 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
92.04% (n=18) vs 38.57% (n=19) placebo @ 32wk16 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
78.36% (n=18) vs 36.82% (n=19) placebo @ 48wk16 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
84.93% (n=33) vs 24.93% (n=36) placebo @ 32wk10 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
85.7% (n=33) vs 30.04% (n=36) placebo @ 48wk10 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
99.71% (n=19) vs 38.57% (n=19) placebo @ 32wk10 mg
NCT06124807 · Phase 2 · registry result, not featured evidence
90.46% (n=19) vs 36.82% (n=19) placebo @ 48wk10 mg
NCT06124807 · Phase 2 · registry result, not featured evidence

survodutide

Weight Loss 15% 54.7% (n=64) vs 5.6% (n=54) placebo @ 46wk4.8 mg
absolute value · percentage points
NCT04667377 · Phase 2 · registry result, not featured evidence
show 3 more results
45.9% (n=61) vs 5.6% (n=54) placebo @ 46wk3.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
37.9% (n=58) vs 5.6% (n=54) placebo @ 46wk2.4 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
12.5% (n=56) vs 5.6% (n=54) placebo @ 46wk0.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
Waist Circumference Change -16.01 vs -3.96 placebo cm @ 46wk4.8 mg
absolute change · cm
NCT04667377 · Phase 2 · registry result, not featured evidence
show 3 more results
-14.96 vs -3.96 placebo cm @ 46wk3.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
-14.99 vs -3.96 placebo cm @ 46wk2.4 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
-8.32 vs -3.96 placebo cm @ 46wk0.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
SBP -8.62 vs -2.46 placebo mmHg @ 46wk4.8 mg
absolute change · mmHg
NCT04667377 · Phase 2 · registry result, not featured evidence
show 3 more results
-8.66 vs -2.46 placebo mmHg @ 46wk3.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
-8.08 vs -2.46 placebo mmHg @ 46wk2.4 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
-6.19 vs -2.46 placebo mmHg @ 46wk0.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
DBP -4.8 vs -1.87 placebo mmHg @ 46wk4.8 mg
absolute change · mmHg
NCT04667377 · Phase 2 · registry result, not featured evidence
show 3 more results
-4.31 vs -1.87 placebo mmHg @ 46wk3.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
-4.36 vs -1.87 placebo mmHg @ 46wk2.4 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
-3.31 vs -1.87 placebo mmHg @ 46wk0.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence

Type 2 Diabetes

Shared mechanism: GLP-1/glucagon receptor (dual) · full Type 2 Diabetes pipeline

mazdutide

Marketed by Innovent Biologics under a licence from Eli Lilly

Phase 3 in Type 2 Diabetespeptide
Reliable signal

NCT05606913 · Phase 3 · completed

This was a randomized, double-blind, active-controlled trial of 731 people with type 2 diabetes. Both mazdutide doses lowered blood sugar (HbA1c) significantly more than the comparator drug dulaglutide, a difference that reached statistical significance.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: December 2027 · NCT07713992 (registry estimate)

Reported efficacy

HbA1c change from baseline at week 28 (Baseline, 28 weeks): HbA1c change from baseline at Week 28: -1.61 percentage points (mazdutide 4mg) and -1.66 percentage points (mazdutide 6mg) vs -1.36 percentage points (dulaglutide 1.5mg); superiority P<.01 for both doses. (met)

Result source: NCT05606913

survodutide

Developed by Boehringer Ingelheim under a licence from Zealand Pharma

Phase 3 in Type 2 Diabetespeptide
Partial signal

NCT06066528 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled Phase 3 trial in adults with obesity and type 2 diabetes (755 enrolled on the registry, 752 randomized in the publication), with co-primary clinical weight-loss endpoints at Week 76. The published primary analysis (treatment-regimen estimand) shows both co-primary endpoints met: mean weight change of -9.8% with 6.0 mg and -8.2% with 3.6 mg versus -3.9% with placebo, and 64.5% and 57.6% versus 35.1% of participants reached at least 5% weight reduction (P<0.001 for all comparisons).

Next expected readout: January 2028 · NCT07754461 (registry estimate)

Reported efficacy

Percentage change in body weight from baseline to Week 76 (Baseline and at Week 76); Achievement of body weight reduction ≥5% (yes/no) from baseline to Week 76 (Baseline and at Week 76): Percentage change in body weight from baseline to Week 76 (SYNCHRONIZE-2, primary analysis, treatment-regimen estimand): -9.8% survodutide 6.0 mg and -8.2% 3.6 mg vs -3.9% placebo; body weight reduction of at least 5%: 64.5% and 57.6% vs 35.1% (P<0.001 for all comparisons with placebo). (met)

Result source: NCT06066528

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointmazdutidesurvodutide
HbA1c, change-2.1% vs -0.1%a−2 vs placebomazdutide 6mg · wk 24NCT05628311
3 other results
  • -1.6% vs -0.1% mazdutide 4mg · wk 24 · Phase 3 · primary NCT05628311
  • -1.7% vs -1.4% mazdutide 6mg · wk 28 · Phase 3 · primary NCT05606913
  • -1.6% vs -1.4% mazdutide 4mg · wk 28 · Phase 3 · primary NCT05606913
-1.7% vs -0.2%−1.4 vs placebo2.7 mg · wk 16 · n 33NCT04153929
5 other results
  • -1.8% vs -0.2% 1.8 mg · wk 16 · n 36 · Phase 2 · primary NCT04153929
  • -1.8% vs -0.2% 1.8 mg twice weekly (3.6 mg) · wk 16 · n 36 · Phase 2 · primary NCT04153929
  • -1.7% vs -0.2% 1.2 mg twice weekly (2.4 mg) · wk 16 · n 44 · Phase 2 · primary NCT04153929
  • -1.4% vs -0.2% 0.9 mg · wk 16 · n 46 · Phase 2 · primary NCT04153929
  • -0.9% vs -0.2% 0.3 mg · wk 16 · n 41 · Phase 2 · primary NCT04153929
Body weight, change (kg)—Not posted · NCT05628311-6.9 vs -1.3−5.6 vs placebo2.7 mg · wk 16 · n 33NCT04153929
5 other results
  • -6.3 vs -1.3 1.8 mg · wk 16 · n 36 · Phase 2 · secondary NCT04153929
  • -8.9 vs -1.3 1.8 mg twice weekly (3.6 mg) · wk 16 · n 37 · Phase 2 · secondary NCT04153929
  • -6.8 vs -1.3 1.2 mg twice weekly (2.4 mg) · wk 16 · n 44 · Phase 2 · secondary NCT04153929
  • -4.4 vs -1.3 0.9 mg · wk 16 · n 46 · Phase 2 · secondary NCT04153929
  • -1.9 vs -1.3 0.3 mg · wk 16 · n 41 · Phase 2 · secondary NCT04153929
HbA1c below 7%—Not posted · NCT05628311—Not posted · NCT06066528
Fasting plasma glucose, change—Not posted · NCT05628311—Not posted · NCT06066528
3-point MACE (% with event)—Not posted · NCT05628311—Not posted · NCT06066528

HbA1c, change

mazdutide
-2.1% vs -0.1%a−2 vs placebomazdutide 6mg · wk 24NCT05628311
3 other results
  • -1.6% vs -0.1% mazdutide 4mg · wk 24 · Phase 3 · primary NCT05628311
  • -1.7% vs -1.4% mazdutide 6mg · wk 28 · Phase 3 · primary NCT05606913
  • -1.6% vs -1.4% mazdutide 4mg · wk 28 · Phase 3 · primary NCT05606913
survodutide
-1.7% vs -0.2%−1.4 vs placebo2.7 mg · wk 16 · n 33NCT04153929
5 other results
  • -1.8% vs -0.2% 1.8 mg · wk 16 · n 36 · Phase 2 · primary NCT04153929
  • -1.8% vs -0.2% 1.8 mg twice weekly (3.6 mg) · wk 16 · n 36 · Phase 2 · primary NCT04153929
  • -1.7% vs -0.2% 1.2 mg twice weekly (2.4 mg) · wk 16 · n 44 · Phase 2 · primary NCT04153929
  • -1.4% vs -0.2% 0.9 mg · wk 16 · n 46 · Phase 2 · primary NCT04153929
  • -0.9% vs -0.2% 0.3 mg · wk 16 · n 41 · Phase 2 · primary NCT04153929

Body weight, change (kg)

mazdutide
—Not posted · NCT05628311
survodutide
-6.9 vs -1.3−5.6 vs placebo2.7 mg · wk 16 · n 33NCT04153929
5 other results
  • -6.3 vs -1.3 1.8 mg · wk 16 · n 36 · Phase 2 · secondary NCT04153929
  • -8.9 vs -1.3 1.8 mg twice weekly (3.6 mg) · wk 16 · n 37 · Phase 2 · secondary NCT04153929
  • -6.8 vs -1.3 1.2 mg twice weekly (2.4 mg) · wk 16 · n 44 · Phase 2 · secondary NCT04153929
  • -4.4 vs -1.3 0.9 mg · wk 16 · n 46 · Phase 2 · secondary NCT04153929
  • -1.9 vs -1.3 0.3 mg · wk 16 · n 41 · Phase 2 · secondary NCT04153929

HbA1c below 7%

mazdutide
—Not posted · NCT05628311
survodutide
—Not posted · NCT06066528

Fasting plasma glucose, change

mazdutide
—Not posted · NCT05628311
survodutide
—Not posted · NCT06066528

3-point MACE (% with event)

mazdutide
—Not posted · NCT05628311
survodutide
—Not posted · NCT06066528
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. mazdutide: 0 of 4 rows · survodutide: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricmazdutidesurvodutide
Dropout rate—
34%2.7 mga
NCT04153929 · Phase 2 · registry result, not featured evidence
show 5 more results
26%1.8 mg twice weekly (3.6 mg)
NCT04153929 · Phase 2 · registry result, not featured evidence
30.8%1.8 mg
NCT04153929 · Phase 2 · registry result, not featured evidence
11.8%1.2 mg twice weekly (2.4 mg)
NCT04153929 · Phase 2 · registry result, not featured evidence
10%0.9 mg
NCT04153929 · Phase 2 · registry result, not featured evidence
18%0.3 mg
NCT04153929 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs—
30%2.7 mga
NCT04153929 · Phase 2 · registry result, not featured evidence
show 5 more results
16%1.8 mg twice weekly (3.6 mg)
NCT04153929 · Phase 2 · registry result, not featured evidence
21.2%1.8 mg
NCT04153929 · Phase 2 · registry result, not featured evidence
7.8%1.2 mg twice weekly (2.4 mg)
NCT04153929 · Phase 2 · registry result, not featured evidence
10%0.9 mg
NCT04153929 · Phase 2 · registry result, not featured evidence
10%0.3 mg
NCT04153929 · Phase 2 · registry result, not featured evidence
Serious AEs—
4%2.7 mga
NCT04153929 · Phase 2 · registry result, not featured evidence
show 5 more results
0%1.8 mg twice weekly (3.6 mg)
NCT04153929 · Phase 2 · registry result, not featured evidence
5.8%1.8 mg
NCT04153929 · Phase 2 · registry result, not featured evidence
2%1.2 mg twice weekly (2.4 mg)
NCT04153929 · Phase 2 · registry result, not featured evidence
8%0.9 mg
NCT04153929 · Phase 2 · registry result, not featured evidence
2%0.3 mg
NCT04153929 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs—
2.7 mga
nausea 46% (placebo 8.5%)
vomiting 26% (placebo 5.1%)
decreased appetite 22% (placebo 3.4%)
NCT04153929 · Phase 2 · registry result, not featured evidence
show 5 more results
1.8 mg twice weekly (3.6 mg)
nausea 46.9% (placebo 8.5%)
decreased appetite 30.6% (placebo 3.4%)
diarrhoea 22.4% (placebo 11.9%)
NCT04153929 · Phase 2 · registry result, not featured evidence
1.8 mg
nausea 48.1% (placebo 8.5%)
vomiting 23.1% (placebo 5.1%)
diarrhoea 17.3% (placebo 11.9%)
NCT04153929 · Phase 2 · registry result, not featured evidence
1.2 mg twice weekly (2.4 mg)
nausea 27.5% (placebo 8.5%)
decreased appetite 17.6% (placebo 3.4%)
constipation 15.7% (placebo 0%)
NCT04153929 · Phase 2 · registry result, not featured evidence
0.9 mg
nausea 28% (placebo 8.5%)
vomiting 18% (placebo 5.1%)
diarrhoea 16% (placebo 11.9%)
NCT04153929 · Phase 2 · registry result, not featured evidence
0.3 mg
diarrhoea 24% (placebo 11.9%)
nausea 20% (placebo 8.5%)
vomiting 14% (placebo 5.1%)
NCT04153929 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

survodutide

Weight -6.68% (n=33) vs -1.2% (n=49) placebo @ 16wk2.7 mg
percent change · % of baseline
NCT04153929 · Phase 2 · registry result, not featured evidence
show 5 more results
-6.63% (n=36) vs -1.2% (n=49) placebo @ 16wk1.8 mg
NCT04153929 · Phase 2 · registry result, not featured evidence
-8.95% (n=37) vs -1.2% (n=49) placebo @ 16wk1.8 mg twice weekly (3.6 mg)
NCT04153929 · Phase 2 · registry result, not featured evidence
-7.16% (n=44) vs -1.2% (n=49) placebo @ 16wk1.2 mg twice weekly (2.4 mg)
NCT04153929 · Phase 2 · registry result, not featured evidence
-4.43% (n=46) vs -1.2% (n=49) placebo @ 16wk0.9 mg
NCT04153929 · Phase 2 · registry result, not featured evidence
-1.86% (n=41) vs -1.2% (n=49) placebo @ 16wk0.3 mg
NCT04153929 · Phase 2 · registry result, not featured evidence
Weight -6.88 vs -1.28 placebo kg @ 16wk2.7 mg
absolute change · kg
NCT04153929 · Phase 2 · registry result, not featured evidence
show 5 more results
-6.31 vs -1.28 placebo kg @ 16wk1.8 mg
NCT04153929 · Phase 2 · registry result, not featured evidence
-8.88 vs -1.28 placebo kg @ 16wk1.8 mg twice weekly (3.6 mg)
NCT04153929 · Phase 2 · registry result, not featured evidence
-6.75 vs -1.28 placebo kg @ 16wk1.2 mg twice weekly (2.4 mg)
NCT04153929 · Phase 2 · registry result, not featured evidence
-4.41 vs -1.28 placebo kg @ 16wk0.9 mg
NCT04153929 · Phase 2 · registry result, not featured evidence
-1.9 vs -1.28 placebo kg @ 16wk0.3 mg
NCT04153929 · Phase 2 · registry result, not featured evidence
Waist Circumference Change -7.47 vs -1.95 placebo cm @ 16wk2.7 mg
absolute change · cm
NCT04153929 · Phase 2 · registry result, not featured evidence
show 5 more results
-3.63 vs -1.95 placebo cm @ 16wk1.8 mg
NCT04153929 · Phase 2 · registry result, not featured evidence
-12.89 vs -1.95 placebo cm @ 16wk1.8 mg twice weekly (3.6 mg)
NCT04153929 · Phase 2 · registry result, not featured evidence
-4.61 vs -1.95 placebo cm @ 16wk1.2 mg twice weekly (2.4 mg)
NCT04153929 · Phase 2 · registry result, not featured evidence
-1.8 vs -1.95 placebo cm @ 16wk0.9 mg
NCT04153929 · Phase 2 · registry result, not featured evidence
-2.73 vs -1.95 placebo cm @ 16wk0.3 mg
NCT04153929 · Phase 2 · registry result, not featured evidence
Weight Loss 5 % 46% (n=50) vs 6.8% (n=59) placebo @ 16wk2.7 mg
absolute value · percentage points
NCT04153929 · Phase 2 · registry result, not featured evidence
show 5 more results
42.3% (n=52) vs 6.8% (n=59) placebo @ 16wk1.8 mg
NCT04153929 · Phase 2 · registry result, not featured evidence
57.1% (n=49) vs 6.8% (n=59) placebo @ 16wk1.8 mg twice weekly (3.6 mg)
NCT04153929 · Phase 2 · registry result, not featured evidence
56.9% (n=51) vs 6.8% (n=59) placebo @ 16wk1.2 mg twice weekly (2.4 mg)
NCT04153929 · Phase 2 · registry result, not featured evidence
38% (n=50) vs 6.8% (n=59) placebo @ 16wk0.9 mg
NCT04153929 · Phase 2 · registry result, not featured evidence
8% (n=50) vs 6.8% (n=59) placebo @ 16wk0.3 mg
NCT04153929 · Phase 2 · registry result, not featured evidence
Weight Loss 10% 16% (n=50) vs 0% (n=59) placebo @ 16wk2.7 mg
responder rate · % of participants
NCT04153929 · Phase 2 · registry result, not featured evidence
show 5 more results
13.5% (n=52) vs 0% (n=59) placebo @ 16wk1.8 mg
NCT04153929 · Phase 2 · registry result, not featured evidence
34.7% (n=49) vs 0% (n=59) placebo @ 16wk1.8 mg twice weekly (3.6 mg)
NCT04153929 · Phase 2 · registry result, not featured evidence
25.5% (n=51) vs 0% (n=59) placebo @ 16wk1.2 mg twice weekly (2.4 mg)
NCT04153929 · Phase 2 · registry result, not featured evidence
6% (n=50) vs 0% (n=59) placebo @ 16wk0.9 mg
NCT04153929 · Phase 2 · registry result, not featured evidence
2% (n=50) vs 0% (n=59) placebo @ 16wk0.3 mg
NCT04153929 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: mazdutide's landscape · survodutide's landscape